Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Merck has acquired exclusive global rights to SPR2015 from SciBrunch under a deal that includes an upfront payment of $400 million and has a total potential aggregate value of $2.13 billion. The transaction has closed and Merck will record a pre-tax charge of $400 million in the third quarter of 2026. SPR2015 is described as a preclinical oral KRAS G12D (ON) inhibitor with reported nanomolar antiproliferative activity and in vivo antitumor efficacy in CDX/PDX models.